Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 2014 Aug 20;32(24):2611-6. doi: 10.1200/JCO.2014.55.4261. Epub 2014 Jul 28.

Incorporating biomarkers into cancer and aging research.

Author information

  • 1Joleen M. Hubbard, Mayo Clinic, Rochester, MN; Harvey J. Cohen, Duke University Medical Center, Durham; and Hyman B. Muss, University of North Carolina, Chapel Hill, NC. hubbard.joleen@mayo.edu.
  • 2Joleen M. Hubbard, Mayo Clinic, Rochester, MN; Harvey J. Cohen, Duke University Medical Center, Durham; and Hyman B. Muss, University of North Carolina, Chapel Hill, NC.

Abstract

The challenge in treating the older adult with cancer is accurately accounting for and adapting management to the heterogeneity in health status of the individual patient. Many oncologists recognize that chronological age alone should not be the determinant when deciding on a treatment regimen. Easily measurable markers that provide an assessment of functional age would be ideal to assess frailty, which may predispose the patient to complications from cancer treatment, including increased toxicity, functional decline, decreased quality of life, and poorer survival. Several categories of potential markers, including chronic inflammatory markers, markers of cellular senescence, and imaging to assess muscle mass to detect sarcopenia, may provide insight into the likelihood of treatment-related complications. This article discusses candidate markers and strategies to evaluate these markers in cancer treatment trials, with the aim of developing a method to assess risk of oncologic outcomes and guide management decisions for both the physician and patient.

PMID:
25071114
PMCID:
PMC4876339
DOI:
10.1200/JCO.2014.55.4261
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Support Center